Cargando…
Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
AIMS: There is limited research using real‐world data to evaluate protective cardiovascular effects of glucagon‐like peptide‐1 (GLP‐1) agonists among adults with type 2 diabetes (T2D) early in treatment. MATERIALS AND METHODS: We conducted a retrospective, active comparator cohort study using 2011–2...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164426/ https://www.ncbi.nlm.nih.gov/pubmed/36825925 http://dx.doi.org/10.1002/edm2.339 |
_version_ | 1785038065962582016 |
---|---|
author | Wallia, Amisha O’Brien, Matthew Hakimian, Stephanie Kang, Raymond Cooper, Andrew Lancki, Nicola Stephen, John J. Aikman, Cassandra Liss, David Parker, Emily Ackermann, Ronald T. |
author_facet | Wallia, Amisha O’Brien, Matthew Hakimian, Stephanie Kang, Raymond Cooper, Andrew Lancki, Nicola Stephen, John J. Aikman, Cassandra Liss, David Parker, Emily Ackermann, Ronald T. |
author_sort | Wallia, Amisha |
collection | PubMed |
description | AIMS: There is limited research using real‐world data to evaluate protective cardiovascular effects of glucagon‐like peptide‐1 (GLP‐1) agonists among adults with type 2 diabetes (T2D) early in treatment. MATERIALS AND METHODS: We conducted a retrospective, active comparator cohort study using 2011–2015 administrative claims data to compare cardiovascular disease (CVD) event rates following initiation of exenatide extended‐release (E‐ER), exenatide immediate‐release (E‐IR) or liraglutide in T2D adults who previously received no other antidiabetic medication (ADM) except metformin. The primary outcome was time to first major adverse CVD event (ischaemic heart disease, stroke, congestive heart failure or peripheral arterial disease) after starting GLP‐1. Cox proportional hazards regression was used to model the association between index GLP‐1 and CVD events, adjusting for baseline patient, prescriber and plan characteristics. Primary analyses included all patients with ≥2 prescription fills for the index GLP‐1, regardless of subsequent refill adherence or initiation of other ADM after index date. RESULTS: Compared with liraglutide, neither E‐ER nor E‐IR was associated with risk of composite major CVD events (hazard ratios [HRs] for E‐ER and E‐IR: 1.33 [95% C.I. 0.73–2.39] and 1.30 [0.81–2.09]). No associations were observed between event rates for individual CVD components. The HR for an ischaemic event with E‐IR relative to liraglutide was 1.85 (95% C.I. 0.97–3.53). Adjusting for time‐varying exposure to other ADM and CVD medications after index date produced similar results. CONCLUSIONS: Initiating either immediate or extended‐release exenatide rather than liraglutide was not associated with significant differences in CVD risk in this observational real‐world study. |
format | Online Article Text |
id | pubmed-10164426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101644262023-05-08 Comparative cardiovascular effects of GLP‐1 agonists using real‐world data Wallia, Amisha O’Brien, Matthew Hakimian, Stephanie Kang, Raymond Cooper, Andrew Lancki, Nicola Stephen, John J. Aikman, Cassandra Liss, David Parker, Emily Ackermann, Ronald T. Endocrinol Diabetes Metab Research Articles AIMS: There is limited research using real‐world data to evaluate protective cardiovascular effects of glucagon‐like peptide‐1 (GLP‐1) agonists among adults with type 2 diabetes (T2D) early in treatment. MATERIALS AND METHODS: We conducted a retrospective, active comparator cohort study using 2011–2015 administrative claims data to compare cardiovascular disease (CVD) event rates following initiation of exenatide extended‐release (E‐ER), exenatide immediate‐release (E‐IR) or liraglutide in T2D adults who previously received no other antidiabetic medication (ADM) except metformin. The primary outcome was time to first major adverse CVD event (ischaemic heart disease, stroke, congestive heart failure or peripheral arterial disease) after starting GLP‐1. Cox proportional hazards regression was used to model the association between index GLP‐1 and CVD events, adjusting for baseline patient, prescriber and plan characteristics. Primary analyses included all patients with ≥2 prescription fills for the index GLP‐1, regardless of subsequent refill adherence or initiation of other ADM after index date. RESULTS: Compared with liraglutide, neither E‐ER nor E‐IR was associated with risk of composite major CVD events (hazard ratios [HRs] for E‐ER and E‐IR: 1.33 [95% C.I. 0.73–2.39] and 1.30 [0.81–2.09]). No associations were observed between event rates for individual CVD components. The HR for an ischaemic event with E‐IR relative to liraglutide was 1.85 (95% C.I. 0.97–3.53). Adjusting for time‐varying exposure to other ADM and CVD medications after index date produced similar results. CONCLUSIONS: Initiating either immediate or extended‐release exenatide rather than liraglutide was not associated with significant differences in CVD risk in this observational real‐world study. John Wiley and Sons Inc. 2023-02-24 /pmc/articles/PMC10164426/ /pubmed/36825925 http://dx.doi.org/10.1002/edm2.339 Text en © 2023 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Wallia, Amisha O’Brien, Matthew Hakimian, Stephanie Kang, Raymond Cooper, Andrew Lancki, Nicola Stephen, John J. Aikman, Cassandra Liss, David Parker, Emily Ackermann, Ronald T. Comparative cardiovascular effects of GLP‐1 agonists using real‐world data |
title | Comparative cardiovascular effects of GLP‐1 agonists using real‐world data |
title_full | Comparative cardiovascular effects of GLP‐1 agonists using real‐world data |
title_fullStr | Comparative cardiovascular effects of GLP‐1 agonists using real‐world data |
title_full_unstemmed | Comparative cardiovascular effects of GLP‐1 agonists using real‐world data |
title_short | Comparative cardiovascular effects of GLP‐1 agonists using real‐world data |
title_sort | comparative cardiovascular effects of glp‐1 agonists using real‐world data |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164426/ https://www.ncbi.nlm.nih.gov/pubmed/36825925 http://dx.doi.org/10.1002/edm2.339 |
work_keys_str_mv | AT walliaamisha comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT obrienmatthew comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT hakimianstephanie comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT kangraymond comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT cooperandrew comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT lanckinicola comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT stephenjohnj comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT aikmancassandra comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT lissdavid comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT parkeremily comparativecardiovasculareffectsofglp1agonistsusingrealworlddata AT ackermannronaldt comparativecardiovasculareffectsofglp1agonistsusingrealworlddata |